Raab & Moskowitz Asset Management LLC Has $6.58 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Posted by Defense World Staff on Apr 10th, 2023

Raab & Moskowitz Asset Management LLC grew its position in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 1.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 128,334 shares of the biopharmaceutical company’s stock after buying an additional 2,131 shares during the quarter. Pfizer accounts for 2.5% of Raab & Moskowitz Asset Management LLC’s portfolio, making the stock its 7th largest position. Raab & Moskowitz Asset Management LLC’s holdings in Pfizer were worth $6,576,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the company. RB Capital Management LLC lifted its position in Pfizer by 6.7% during the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after purchasing an additional 341 shares during the period. Ironwood Wealth Management LLC. grew its holdings in shares of Pfizer by 1.1% in the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after acquiring an additional 400 shares during the period. United Bank increased its position in Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after acquiring an additional 290 shares during the last quarter. Ergoteles LLC boosted its position in Pfizer by 136.3% in the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after purchasing an additional 21,209 shares during the last quarter. Finally, Mackenzie Financial Corp increased its position in shares of Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after purchasing an additional 79,887 shares during the last quarter. 67.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have commented on the stock. StockNews.com assumed coverage on shares of Pfizer in a report on Thursday, March 16th. They set a “buy” rating for the company. Wells Fargo & Company lowered their price target on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a report on Friday, March 17th. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and set a $51.00 price objective for the company in a research note on Tuesday, February 7th. UBS Group set a $45.00 target price on shares of Pfizer in a report on Tuesday, March 14th. Finally, Bank of America cut Pfizer from a “buy” rating to a “neutral” rating and set a $60.00 target price for the company. in a research report on Wednesday, January 4th. Eight investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Pfizer has an average rating of “Hold” and an average target price of $49.93.

Insider Activity at Pfizer

In related news, major shareholder Pfizer Inc purchased 1,811,594 shares of the business’s stock in a transaction on Friday, March 17th. The shares were acquired at an average price of $2.76 per share, for a total transaction of $4,999,999.44. Following the purchase, the insider now owns 5,952,263 shares of the company’s stock, valued at approximately $16,428,245.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.05% of the stock is currently owned by corporate insiders.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $41.50 on Monday. The company has a quick ratio of 1.00, a current ratio of 1.22 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $234.24 billion, a price-to-earnings ratio of 7.57, a price-to-earnings-growth ratio of 1.40 and a beta of 0.64. The firm has a 50 day moving average of $41.66 and a 200 day moving average of $45.47. Pfizer Inc. has a 52 week low of $39.23 and a 52 week high of $56.32.

Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 EPS for the quarter, topping the consensus estimate of $1.03 by $0.11. The firm had revenue of $24.30 billion during the quarter, compared to analyst estimates of $24.40 billion. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.08 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 3.3 earnings per share for the current fiscal year.

About Pfizer

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.